Y. Zaripova, O. L. Igo, E.G. Mikhaylovskaya, N. B. Guseva, S. S. Nikitin, M. A. Mushkatina, T. Varlamova, V. Korneva
{"title":"Familial hypercholesterolemia in pediatric practice","authors":"Y. Zaripova, O. L. Igo, E.G. Mikhaylovskaya, N. B. Guseva, S. S. Nikitin, M. A. Mushkatina, T. Varlamova, V. Korneva","doi":"10.20953/1817-7646-2023-3-127-132","DOIUrl":null,"url":null,"abstract":"Familial hypercholesterolemia (FH) is a hereditary disease characterized by elevated levels of low-density lipoproteins, early onset and progressive course of atherosclerosis (usually at a young age), and high risk of cardiovascular complications. Detection of mutations in family members enables the diagnosis of FH. However, approximately 20% of FH patients are tested negative for the FH-associated mutations. This results in a delayed diagnosis and late therapy initiation, especially in children. Therefore, raising awareness about FH both among healthcare professionals and in the society is very important. Key words: children, lipid-lowering therapy, familial hypercholesterolemia, screening, registry","PeriodicalId":38157,"journal":{"name":"Voprosy Prakticheskoi Pediatrii","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy Prakticheskoi Pediatrii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1817-7646-2023-3-127-132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Familial hypercholesterolemia (FH) is a hereditary disease characterized by elevated levels of low-density lipoproteins, early onset and progressive course of atherosclerosis (usually at a young age), and high risk of cardiovascular complications. Detection of mutations in family members enables the diagnosis of FH. However, approximately 20% of FH patients are tested negative for the FH-associated mutations. This results in a delayed diagnosis and late therapy initiation, especially in children. Therefore, raising awareness about FH both among healthcare professionals and in the society is very important. Key words: children, lipid-lowering therapy, familial hypercholesterolemia, screening, registry